You are here: Home » News-CM » Equities » Hot Pursuit
Business Standard

Tatva Chintan Pharma Q2 PAT soars 811% YoY to Rs 32 cr

Capital Market 

Tatva Chintan Pharma Chem reported an 811% jump in consolidated net profit to Rs 32.4 crore on a 105.8% rise in revenue from operations to Rs 123.6 crore in Q2 FY22 over Q2 FY21.

On a sequential basis, the company posted a 40% rise in net profit on a 15.7% increase in revenue from operations to Rs 1,236.15 crore in Q2 FY22 over Q1 FY22. Profit before tax jumped nearly 46% quarter on quarter and 527% year on year to Rs 35.4 crore in Q2 FY22.

Tatva Chintan Pharma Chem is a specialty chemicals manufacturing company engaged in the manufacturing of a diverse portfolio of structure directing agents (SDAs), phase transfer catalysts (PTCs), electrolyte salts for super capacitor batteries and pharmaceutical and agrochemical intermediates and other specialty chemicals (PASC). It is the largest and only commercial manufacturer of SDAs for zeolites in India.

Tatva Chintan closed 0.59% lower at Rs 2,132.05 on Friday.

Shares of Tatva Chintan Pharma Chem entered bourses on 29 July 2021. The scrip was listed at a price of Rs 2,111.80 per share, at a premium of 95% to the initial public offer (IPO) price of Rs 1,083. The IPO of specialty chemicals manufacturing company received bids for 58.83 crore shares as against 32.61 lakh shares on offer. The issue was subscribed 180.36 times. The issue opened for bidding on 16 July 2021 and closed on 20 July 2021. The price band of the IPO was fixed at Rs 1073-1083 per share.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Sat, October 23 2021. 15:43 IST